ECSP22001370A - Inhibidores de prmt5 - Google Patents

Inhibidores de prmt5

Info

Publication number
ECSP22001370A
ECSP22001370A ECSENADI20221370A ECDI202201370A ECSP22001370A EC SP22001370 A ECSP22001370 A EC SP22001370A EC SENADI20221370 A ECSENADI20221370 A EC SENADI20221370A EC DI202201370 A ECDI202201370 A EC DI202201370A EC SP22001370 A ECSP22001370 A EC SP22001370A
Authority
EC
Ecuador
Prior art keywords
overexpression
disorders
prmt5
prmt5 inhibitors
relates
Prior art date
Application number
ECSENADI20221370A
Other languages
English (en)
Inventor
Rajender Kumar Kamboj
Chaitanya Kulkarni
Dipak Lagad
Mahadeo Tryambake
Chetan Pawar
Milind Sindkhedkar
Ganesh Gudade
Prathap Nair
Venkata Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP22001370A publication Critical patent/ECSP22001370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a análogos de nucleósidos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5.
ECSENADI20221370A 2019-06-10 2022-01-07 Inhibidores de prmt5 ECSP22001370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921022971 2019-06-10
IN201921022972 2019-06-10

Publications (1)

Publication Number Publication Date
ECSP22001370A true ECSP22001370A (es) 2022-02-25

Family

ID=71670318

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20221370A ECSP22001370A (es) 2019-06-10 2022-01-07 Inhibidores de prmt5

Country Status (30)

Country Link
US (1) US12391695B2 (es)
EP (1) EP3980417B1 (es)
JP (1) JP7686579B2 (es)
KR (1) KR20220019781A (es)
CN (1) CN114026094B (es)
AU (1) AU2020293021B2 (es)
BR (1) BR112021024999A2 (es)
CA (1) CA3141748A1 (es)
CL (1) CL2021003292A1 (es)
CO (1) CO2022000061A2 (es)
CR (1) CR20220010A (es)
CY (1) CY1126537T1 (es)
DK (1) DK3980417T3 (es)
EC (1) ECSP22001370A (es)
ES (1) ES2967457T3 (es)
FI (1) FI3980417T3 (es)
HR (1) HRP20231673T1 (es)
HU (1) HUE064493T2 (es)
IL (1) IL288401A (es)
LT (1) LT3980417T (es)
MX (1) MX2021015262A (es)
PE (1) PE20230245A1 (es)
PH (1) PH12021553082A1 (es)
PL (1) PL3980417T3 (es)
PT (1) PT3980417T (es)
RS (1) RS64972B1 (es)
SI (1) SI3980417T1 (es)
SM (1) SMT202400014T1 (es)
WO (1) WO2020250123A1 (es)
ZA (1) ZA202109573B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230066014A1 (en) * 2019-12-03 2023-03-02 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025051157A1 (zh) * 2023-09-06 2025-03-13 赛诺哈勃药业（成都）有限公司 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
FR3161349B1 (fr) * 2024-04-17 2026-04-10 Univ Sorbonne Nouveaux inhibiteurs des transporteurs de cations organiques pour le traitement des troubles de l’humeur
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57163383A (en) * 1980-12-12 1982-10-07 Toyo Jozo Co Ltd Neplanocin a derivative
US4975434A (en) 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
EP1252160B1 (en) 2000-01-14 2006-08-16 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methanocarba cycloalkyl nucleoside analogues
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AU2008334705B2 (en) 2007-12-11 2011-06-16 F. Hoffmann-La Roche Ag Inhibitors of stearoyl-CoA desaturase
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
PL3050874T3 (pl) 2008-11-14 2019-07-31 Merial Inc. Wzbogacone enancjomerycznie aryloazol-2-ilocyjanoetyloaminowe związki pasożytobójcze
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
KR101789129B1 (ko) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2013157022A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
JP6559123B2 (ja) 2013-10-10 2019-08-14 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの阻害剤
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
PL3160958T3 (pl) 2014-06-25 2021-07-19 Glaxosmithkline Intellectual Property Development Limited Krystaliczne sole (s)-6-((1-acetylopiperydyn-4-ylo)amino)-n-(3-(3,4-dihydroizochinolin-2(1h)-ylo)-2-hydroksypropylo)pirymi­dyno-4-karboksyamidu
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10653693B2 (en) 2014-08-04 2020-05-19 Epizyme, Inc. PRMT5 inhibitors and uses thereof
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
CN108473012B (zh) 2015-12-11 2022-05-03 伊顿智能动力有限公司 自主停靠系统
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11220524B2 (en) 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3596051B1 (en) 2017-03-13 2022-04-27 Impetis Biosciences Ltd. Fused bicyclic compounds, compositions and applications thereof
CR20200263A (es) * 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
US20230066014A1 (en) * 2019-12-03 2023-03-02 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors

Also Published As

Publication number Publication date
CY1126537T1 (el) 2026-02-25
BR112021024999A2 (pt) 2022-01-25
KR20220019781A (ko) 2022-02-17
US12391695B2 (en) 2025-08-19
LT3980417T (lt) 2023-12-27
CA3141748A1 (en) 2020-12-17
EP3980417A1 (en) 2022-04-13
PL3980417T3 (pl) 2024-03-18
CL2021003292A1 (es) 2022-08-19
JP7686579B2 (ja) 2025-06-02
US20220315589A1 (en) 2022-10-06
SMT202400014T1 (it) 2024-03-13
AU2020293021A1 (en) 2021-12-23
CN114026094A (zh) 2022-02-08
PH12021553082A1 (en) 2023-09-11
CO2022000061A2 (es) 2022-04-08
PE20230245A1 (es) 2023-02-07
AU2020293021B2 (en) 2025-10-02
RS64972B1 (sr) 2024-01-31
ZA202109573B (en) 2022-11-30
IL288401A (en) 2022-01-01
DK3980417T3 (en) 2023-12-18
HRP20231673T1 (hr) 2024-03-15
MX2021015262A (es) 2022-04-06
CR20220010A (es) 2022-05-13
JP2022536337A (ja) 2022-08-15
PT3980417T (pt) 2023-12-28
WO2020250123A1 (en) 2020-12-17
ES2967457T3 (es) 2024-04-30
FI3980417T3 (fi) 2023-12-28
SI3980417T1 (sl) 2024-02-29
EP3980417B1 (en) 2023-09-27
HUE064493T2 (hu) 2024-03-28
CN114026094B (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
CO2022000061A2 (es) Inhibidores de prmt5
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
MX2023007192A (es) Inhibidores de prmt5.
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
EA202193015A1 (ru) Ингибиторы cdk
MX2021011606A (es) Compuestos dirigidos a prmt5.
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2022002443A (es) Compuestos inhibidores de perk.